Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19779078 | 0.91 | HTT (0.33) | HTT | |
| SCHEMBL19420677 | 0.88 | PAK1 (0.34) | HTT | |
| SCHEMBL18879374 | 0.87 | HTT (0.31) | HTT | |
| SCHEMBL19618176 | 0.84 | HTT (0.31) | HTT | |
| SCHEMBL21945762 | 0.81 | PAK1 (0.33) | HTT | |
| SCHEMBL19261349 | 0.80 | HTT (0.31) | HTT | |
| SCHEMBL6745188 | 0.80 | HPGD (0.30) | — | |
| SCHEMBL130108 | 0.79 | HPGD (0.39) | — | |
| SCHEMBL19727251 | 0.79 | HTT (0.31) | HTT | |
| SCHEMBL19618145 | 0.78 | HPGD (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20190144446-A1 | FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2019-05-16 | — | — | US | disclosed |
| EP-3013798-B1 | FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS | BEIGENE LTD (KY) | 2018-06-27 | — | — | EP | disclosed |
| US-20180015093-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. | 2018-01-18 | — | — | US | disclosed |
| US-20170360795-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-9822131-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2017-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144446-A1 | FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS | BRAF, RAF1, ARAF | HTT 3345/4885 |
| US-20170360795-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | HTT 3415/4885 |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | HTT 3415/4885 |
| US-20180015093-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | HTT 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.